Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade
Overexpression of human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive marker of response to anti-HER2 therapy in breast cancer. Our goal was to analyze the prognostic significance of moderate expression of HER2 in breast cancer with intermediate differentiation...
Gespeichert in:
| Veröffentlicht in: | Breast cancer research and treatment 2015-06, Vol.151 (2), p.357-364 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 364 |
|---|---|
| container_issue | 2 |
| container_start_page | 357 |
| container_title | Breast cancer research and treatment |
| container_volume | 151 |
| creator | Ignatov, Tanja Eggemann, Holm Burger, Elke Fettke, Franziska Costa, Serban Dan Ignatov, Atanas |
| description | Overexpression of human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive marker of response to anti-HER2 therapy in breast cancer. Our goal was to analyze the prognostic significance of moderate expression of HER2 in breast cancer with intermediate differentiation grade. We performed a multicenter retrospective register study of 8494 patients with primary non-metastatic breast cancer admitted between 2000 and 2011 to eight Clinics in Saxony-Anhalt, federal state of Germany. Patients were divided into three groups according to their HER2 score: 4073 were classified as HER2 negative (HER2 0 and 1+), 822 HER2 moderate (HER2 2+/
HER2
), and 1238 HER2 positive (HER2 3+ or HER2 2+/
HER2
+). HER2-positive cases were excluded from analysis. Tumors with moderate HER2 (HER2 2+) expression demonstrated an aggressive behavior and worse patient survival compared with HER2 0 and 1+ status. HER2 2+ status was associated with shorter median overall survival (OS) (
P
|
| doi_str_mv | 10.1007/s10549-015-3407-2 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1681264457</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A435334948</galeid><sourcerecordid>A435334948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-8691c06fb9e5d0210a79369d63add9d9c4892f61c85da846af0acfdd7a1235153</originalsourceid><addsrcrecordid>eNp1ksuKFDEUhoMoTtv6AG4kIIibGnOpSlWWwzAXYUQQXYd0clKdpjppk5SXtzdljzojShYhJ9_5OZcfoeeUnFJC-jeZkq6VDaFdw1vSN-wBWtGu503PaP8QrQgVfSMGIk7Qk5x3hBDZE_kYnbBOMsH5sEK7d9FC0gXwBF9gwtHh64sPDMO3Q4KcfQxYB4t9yfiQ4hhiLt7g7MfgnTc6GMA-4E0CnQv--U74qy_bGi2Q9mD9oj0mbeEpeuT0lOHZ7b1Gny4vPp5fNzfvr96en900pmtJaQYhqSHCbSR0ljBKdC-5kFZwba200rSDZE5QM3RWD63QjmjjrO01ZbyjHV-j10fdWvDnGXJRe58NTJMOEOesqBgoE21bB7VGL_9Cd3FOoVa3UERS2Q7kDzXqCZQPLpakzSKqzlrecd5WrFKn_6DqsbD3JgZwvsbvJby6k7AFPZVtjtNc6tDzfZAeQZNizgmcOiS_1-m7okQtRlBHI6hqBLUYQbGa8-K2s3lTt_A749fmK8COQK5fYYR0p_X_qv4AcMO7TQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1680919480</pqid></control><display><type>article</type><title>Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Ignatov, Tanja ; Eggemann, Holm ; Burger, Elke ; Fettke, Franziska ; Costa, Serban Dan ; Ignatov, Atanas</creator><creatorcontrib>Ignatov, Tanja ; Eggemann, Holm ; Burger, Elke ; Fettke, Franziska ; Costa, Serban Dan ; Ignatov, Atanas</creatorcontrib><description>Overexpression of human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive marker of response to anti-HER2 therapy in breast cancer. Our goal was to analyze the prognostic significance of moderate expression of HER2 in breast cancer with intermediate differentiation grade. We performed a multicenter retrospective register study of 8494 patients with primary non-metastatic breast cancer admitted between 2000 and 2011 to eight Clinics in Saxony-Anhalt, federal state of Germany. Patients were divided into three groups according to their HER2 score: 4073 were classified as HER2 negative (HER2 0 and 1+), 822 HER2 moderate (HER2 2+/
HER2
), and 1238 HER2 positive (HER2 3+ or HER2 2+/
HER2
+). HER2-positive cases were excluded from analysis. Tumors with moderate HER2 (HER2 2+) expression demonstrated an aggressive behavior and worse patient survival compared with HER2 0 and 1+ status. HER2 2+ status was associated with shorter median overall survival (OS) (
P
< 0.0001) in breast cancer patients with an intermediate grade of differentiation. Comparing low-grade and high-grade tumors, HER2 moderate expression did not significantly influence patient survival. In multivariate analysis after adjustment for other prognostic factors HER2 2+ status remained an unfavorable prognostic factor for OS (HR 1.224, 95 % CI 1.059–1.415,
P
= 0.006) in breast cancer patients with an intermediate grade of differentiation. HER2 2+ status is an unfavorable prognostic factor regarding the OS of breast cancer patients with intermediate grade of differentiation and could be used to identify patients, who may benefit from adjuvant therapy.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-015-3407-2</identifier><identifier>PMID: 25926338</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis ; Biomarkers, Tumor ; Breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms - mortality ; Breast Neoplasms - pathology ; Breast Neoplasms - therapy ; Cancer research ; Cancer therapies ; Clinical Trial ; Epidermal growth factor ; Female ; Gene Expression ; Germany - epidemiology ; Health aspects ; Humans ; Kaplan-Meier Estimate ; Lymphatic Metastasis ; Medical prognosis ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Grading ; Oncology ; Prognosis ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; Risk Factors ; Tumor Burden ; Young Adult</subject><ispartof>Breast cancer research and treatment, 2015-06, Vol.151 (2), p.357-364</ispartof><rights>Springer Science+Business Media New York 2015</rights><rights>COPYRIGHT 2015 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-8691c06fb9e5d0210a79369d63add9d9c4892f61c85da846af0acfdd7a1235153</citedby><cites>FETCH-LOGICAL-c540t-8691c06fb9e5d0210a79369d63add9d9c4892f61c85da846af0acfdd7a1235153</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-015-3407-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-015-3407-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,777,781,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25926338$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ignatov, Tanja</creatorcontrib><creatorcontrib>Eggemann, Holm</creatorcontrib><creatorcontrib>Burger, Elke</creatorcontrib><creatorcontrib>Fettke, Franziska</creatorcontrib><creatorcontrib>Costa, Serban Dan</creatorcontrib><creatorcontrib>Ignatov, Atanas</creatorcontrib><title>Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>Overexpression of human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive marker of response to anti-HER2 therapy in breast cancer. Our goal was to analyze the prognostic significance of moderate expression of HER2 in breast cancer with intermediate differentiation grade. We performed a multicenter retrospective register study of 8494 patients with primary non-metastatic breast cancer admitted between 2000 and 2011 to eight Clinics in Saxony-Anhalt, federal state of Germany. Patients were divided into three groups according to their HER2 score: 4073 were classified as HER2 negative (HER2 0 and 1+), 822 HER2 moderate (HER2 2+/
HER2
), and 1238 HER2 positive (HER2 3+ or HER2 2+/
HER2
+). HER2-positive cases were excluded from analysis. Tumors with moderate HER2 (HER2 2+) expression demonstrated an aggressive behavior and worse patient survival compared with HER2 0 and 1+ status. HER2 2+ status was associated with shorter median overall survival (OS) (
P
< 0.0001) in breast cancer patients with an intermediate grade of differentiation. Comparing low-grade and high-grade tumors, HER2 moderate expression did not significantly influence patient survival. In multivariate analysis after adjustment for other prognostic factors HER2 2+ status remained an unfavorable prognostic factor for OS (HR 1.224, 95 % CI 1.059–1.415,
P
= 0.006) in breast cancer patients with an intermediate grade of differentiation. HER2 2+ status is an unfavorable prognostic factor regarding the OS of breast cancer patients with intermediate grade of differentiation and could be used to identify patients, who may benefit from adjuvant therapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - mortality</subject><subject>Breast Neoplasms - pathology</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer research</subject><subject>Cancer therapies</subject><subject>Clinical Trial</subject><subject>Epidermal growth factor</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Germany - epidemiology</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphatic Metastasis</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Oncology</subject><subject>Prognosis</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Risk Factors</subject><subject>Tumor Burden</subject><subject>Young Adult</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1ksuKFDEUhoMoTtv6AG4kIIibGnOpSlWWwzAXYUQQXYd0clKdpjppk5SXtzdljzojShYhJ9_5OZcfoeeUnFJC-jeZkq6VDaFdw1vSN-wBWtGu503PaP8QrQgVfSMGIk7Qk5x3hBDZE_kYnbBOMsH5sEK7d9FC0gXwBF9gwtHh64sPDMO3Q4KcfQxYB4t9yfiQ4hhiLt7g7MfgnTc6GMA-4E0CnQv--U74qy_bGi2Q9mD9oj0mbeEpeuT0lOHZ7b1Gny4vPp5fNzfvr96en900pmtJaQYhqSHCbSR0ljBKdC-5kFZwba200rSDZE5QM3RWD63QjmjjrO01ZbyjHV-j10fdWvDnGXJRe58NTJMOEOesqBgoE21bB7VGL_9Cd3FOoVa3UERS2Q7kDzXqCZQPLpakzSKqzlrecd5WrFKn_6DqsbD3JgZwvsbvJby6k7AFPZVtjtNc6tDzfZAeQZNizgmcOiS_1-m7okQtRlBHI6hqBLUYQbGa8-K2s3lTt_A749fmK8COQK5fYYR0p_X_qv4AcMO7TQ</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Ignatov, Tanja</creator><creator>Eggemann, Holm</creator><creator>Burger, Elke</creator><creator>Fettke, Franziska</creator><creator>Costa, Serban Dan</creator><creator>Ignatov, Atanas</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20150601</creationdate><title>Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade</title><author>Ignatov, Tanja ; Eggemann, Holm ; Burger, Elke ; Fettke, Franziska ; Costa, Serban Dan ; Ignatov, Atanas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-8691c06fb9e5d0210a79369d63add9d9c4892f61c85da846af0acfdd7a1235153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - mortality</topic><topic>Breast Neoplasms - pathology</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer research</topic><topic>Cancer therapies</topic><topic>Clinical Trial</topic><topic>Epidermal growth factor</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Germany - epidemiology</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphatic Metastasis</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Oncology</topic><topic>Prognosis</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Risk Factors</topic><topic>Tumor Burden</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ignatov, Tanja</creatorcontrib><creatorcontrib>Eggemann, Holm</creatorcontrib><creatorcontrib>Burger, Elke</creatorcontrib><creatorcontrib>Fettke, Franziska</creatorcontrib><creatorcontrib>Costa, Serban Dan</creatorcontrib><creatorcontrib>Ignatov, Atanas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ignatov, Tanja</au><au>Eggemann, Holm</au><au>Burger, Elke</au><au>Fettke, Franziska</au><au>Costa, Serban Dan</au><au>Ignatov, Atanas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2015-06-01</date><risdate>2015</risdate><volume>151</volume><issue>2</issue><spage>357</spage><epage>364</epage><pages>357-364</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>Overexpression of human epidermal growth factor receptor 2 (HER2) is an important prognostic and predictive marker of response to anti-HER2 therapy in breast cancer. Our goal was to analyze the prognostic significance of moderate expression of HER2 in breast cancer with intermediate differentiation grade. We performed a multicenter retrospective register study of 8494 patients with primary non-metastatic breast cancer admitted between 2000 and 2011 to eight Clinics in Saxony-Anhalt, federal state of Germany. Patients were divided into three groups according to their HER2 score: 4073 were classified as HER2 negative (HER2 0 and 1+), 822 HER2 moderate (HER2 2+/
HER2
), and 1238 HER2 positive (HER2 3+ or HER2 2+/
HER2
+). HER2-positive cases were excluded from analysis. Tumors with moderate HER2 (HER2 2+) expression demonstrated an aggressive behavior and worse patient survival compared with HER2 0 and 1+ status. HER2 2+ status was associated with shorter median overall survival (OS) (
P
< 0.0001) in breast cancer patients with an intermediate grade of differentiation. Comparing low-grade and high-grade tumors, HER2 moderate expression did not significantly influence patient survival. In multivariate analysis after adjustment for other prognostic factors HER2 2+ status remained an unfavorable prognostic factor for OS (HR 1.224, 95 % CI 1.059–1.415,
P
= 0.006) in breast cancer patients with an intermediate grade of differentiation. HER2 2+ status is an unfavorable prognostic factor regarding the OS of breast cancer patients with intermediate grade of differentiation and could be used to identify patients, who may benefit from adjuvant therapy.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>25926338</pmid><doi>10.1007/s10549-015-3407-2</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-6806 |
| ispartof | Breast cancer research and treatment, 2015-06, Vol.151 (2), p.357-364 |
| issn | 0167-6806 1573-7217 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1681264457 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Aged Aged, 80 and over Analysis Biomarkers, Tumor Breast cancer Breast Neoplasms - genetics Breast Neoplasms - mortality Breast Neoplasms - pathology Breast Neoplasms - therapy Cancer research Cancer therapies Clinical Trial Epidermal growth factor Female Gene Expression Germany - epidemiology Health aspects Humans Kaplan-Meier Estimate Lymphatic Metastasis Medical prognosis Medicine Medicine & Public Health Middle Aged Neoplasm Grading Oncology Prognosis Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Risk Factors Tumor Burden Young Adult |
| title | Moderate level of HER2 expression and its prognostic significance in breast cancer with intermediate grade |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T21%3A21%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Moderate%20level%20of%20HER2%20expression%20and%20its%20prognostic%20significance%20in%20breast%20cancer%20with%20intermediate%20grade&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Ignatov,%20Tanja&rft.date=2015-06-01&rft.volume=151&rft.issue=2&rft.spage=357&rft.epage=364&rft.pages=357-364&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-015-3407-2&rft_dat=%3Cgale_proqu%3EA435334948%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1680919480&rft_id=info:pmid/25926338&rft_galeid=A435334948&rfr_iscdi=true |